


What's New in Obstetric Anesthesia

SFOAI Varmote 2023
Skåvsjöholm



Lawrence C. Tsen, MD

Director of Anesthesia, Center for Reproductive Medicine,
Director, Human Research Office, Brigham and Women's Hospital
Associate Professor in Anaesthesia, Harvard Medical School



MORBIDITIES
REGIONAL
SECTION
NOVEL

No Disclosures

SpaceX, Boeing, Virgin Galactica,
Orbital Sciences, Sierra Nevada Corp

MORBIDITIES



Morbidity



Preeclampsia


Role: Preexisting CV Disease
Prevalence 2-8% All Pregnancies
Swedish Prevalence (2007-12) 2.9%
US Maternal Deaths (2011-15) 7%

Morbidity: Preeclampsia Mechanism

Preeclampsia

Mechanism


Na + Angio II Sensitivity
Sympathetic Activation
Endothelial Dysfunction
Inflammasomes



Morbidity: Preeclampsia Result + Treatment




Maternal	Fetal
HTN, CAD, Stroke, ESRD	IUGR



Jung E, et al. Etiology of Preeclampsia. Am J Obstet Gynecol 2022; Chappell LC, et al. Lancet 2021;398:341-54; Magee LA, et al. Preeclampsia: NEJM 2022

Morbidity



Placenta
Accreta
Spectrum


Driver: Rise in CD

CD Global rate: (1966-97) 400% increase

CD Sweden rate (2022): 18.6%

CD Global rate by 2030, 28.5%

Morbidity: Placenta Accreta Spectrum Mechanism





Mechanism

Old: Extravillous trophoblast (EVT) invasion

PAS New: **Loss of subdecidual** myometrium
Development of **anchoring villi** through gaps
High pressure arterial inflow, **placental lacunae**,
fibrinoid accumulation in 70%

Morbidity: Placenta Accreta Spectrum Treatment




Trimester	Modality	Notes
1st	Blood	ATT3, plasminogen, clustered trophoblasts
2nd	Ultrasound	Sensitivity 88-97%

Mortality


Maternal Mortality Ratio:

- 43% Global Reduction
- 3-5% Developed Countries **Increase**
- 50% **Improvable** Factors
- 84% **Preventable**-CDC



Delayed Consult /Diagnosis
Delayed Referral/Advanced Care
Communication /Management

Morbidity and Mortality



A close-up photograph of a hand holding a bright yellow egg over a control panel. The control panel is light grey with a black outline and features several buttons. One button is prominently labeled 'REGIONAL' in bold black capital letters. Other buttons are visible but out of focus, including one with the number '1'. The hand is positioned in the bottom right corner, with the thumb and index finger gripping the egg. The background is dark and indistinct.

REGIONAL

ASA Quality Metrics: Obstetric Anesthesia

Neuraxial Analgesia

- Labor Analgesia Request Responsiveness
- Labor Epidural Replacements
- Post Dural Puncture Headache Accountability

Response: Infection, Coagulation, Preparation

Infection

Bacterial: Antibiotic Prophylaxis (ie. GBS, Chorioamnionitis)

Viral: COVID 19: Pro-Coagulation: PE 16.5%, DVT 14.8%

Anti-Coagulation: Thrombocytopenia

Joo Suh Y, et al. PE + DVT in COVID 19, Radiology 2020
Agostinis C, et al. COVID 19, Preeclampsia, Complement System. Front Immune 2021
SOAP Consensus Statement Pregnant/Postpartum on Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg 2018. Ashken T, West S: BJA Educ 2021

Response: Infection, Coagulation, Preparation

Infection

Bacterial: Antibiotic Prophylaxis (ie. Chorioamnionitis)

Viral: COVID 19: Pro-Coagulation: PE 16.5%, DVT 14.8%

Anti-Coagulation: Thrombocytopenia

Coagulation

Antiplatelet/Anticoagulant

Thrombocytopenia

Joo Suh Y, et al. PE + DVT in COVID 19, Radiology 2020

Agostinis C, et al. COVID 19, Preeclampsia, Complement System. Front Immune 2021

SOAP Consensus Statement Pregnant/Postpartum on Thromboprophylaxis or Higher Dose Anticoagulants

Anesth Analg 2018. Ashken T, West S: BJA Educ 2021




Figure 1. Plasma heparin concentrations in 6 pregnant women at mean gestational age 27 weeks, versus 6 nonpregnant women, after a single dose of weight-adjusted UFH SQ (mean \pm standard error of 9500 ± 640 U). SQ indicates subcutaneous; UFH, unfractionated heparin.

Response: Infection, **Coagulation**, Preparation

Thrombocytopenia: Number, **Rate of Change**, Etiology

Quantitative + Qualitative Deficit: **Destruction**, NonImmune Infection, DIC, Sepsis, TTP, Uremia, **Gest**, **PIH**

Consider **Functional Assays** (TEG, Platelet Function Assays)

Risks/Benefits

Hematoma 0.6%


(<1:1500) vs GA

Complications 6.5%

Platelet	Recommendation	Hematoma 95% CI
70 to 99 K	Reasonable to proceed	0 to 0.19%
50 to 69 K	Risk/benefit analysis	0 to 2.6%
0 to 49 K	Reasonable to avoid	0 to 9%

Bauer ME, et al. SOAP Interdisciplinary Consensus Statement Neuraxial Techniques in Obstetric Patients with Thrombocytopenia, 2021 (ASRA, ACOG, SMFM)

Response: Infection, Coagulation, Preparation



Better epidural space identity + depth = safety, efficacy, failures

Limited experience and real-time guidance

Perlas et al. Systematic Review and MetaAnalysis. RAPM 2016; Van de Putte, P. POC
 UltrasoundL Gastric, Airway, Neuraxial, Cardioresp. Curr Opin Anaesthesiol 2002


Labor Epidural Replacement: Neuraxial Technique

Failed Blocks	Epidural	CSE	DPE	Needle
Eappen n = 4240	13.1%	7.2%		25G
Norris n = 1660	1.3%	0.2%		25G
Van de Velde n = 661/2075	3.18%	1.49%		27, 29G
Thomas n = 248	9.3%	8%		27G
Booth n = 955/1440	11.6%	6.6%		27G
Berger n = 1548		9.7%	6.4%	25G


Eappen IJOA 1998; Norris IJOA 2000; Van de Velde Anaesth Intens Care 2001
 Thomas Anesth 2005; Bauer, Tsen IJOA 2012; Booth Anesth 2016; Berger, IJOA 2022

Labor Epidural Replacement: Neuraxial Technique

	CSE	DPE	EPIDURAL
NONE	20 (50%)	31 (77.5%)	20 (50%)
ONE or MORE	20 (50%)	9 (22.5%)	20 (50%)
TIME TO TOP-UP	132 ± 85	250 ± 163	207 ± 133



Cath Adjust
p = 0.61



Cath Replace
p = 0.59

PDPH Epidural Blood Patch

	Partial success				Failure			
	Unadjusted*		Adjusted†		Unadjusted*		Adjusted†	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Previous history of migraine headache								
No	Reference		Reference		Reference		Reference	
Yes	1.06 (0.57–1.95)	0.86	1.25 (0.61–2.56)	0.55	2.09 (1.16–3.78)	0.0149	3.16 (1.48–6.78)	0.0032
Level of accidental dural puncture								
L3/L5	Reference		Reference		Reference		Reference	
L1/L3	1.83 (1.12–2.98)	0.0152	2.69 (1.47–4.94)	0.0014	2.11 (1.23–3.60)	0.0065	3.28 (1.64–6.53)	0.0008
Time from accidental dural puncture to epidural blood patch (h)								
<48	Reference		Reference		Reference		Reference	
48 to <72	0.70 (0.38–1.28)	0.24	0.60 (0.30–1.19)	0.14	0.43 (0.23–0.78)	0.0060	0.37 (0.18–0.77)	0.0073
≥72	0.45 (0.25–0.78)	0.0046	0.36 (0.19–0.70)	0.0022	0.10 (0.06–0.19)	<0.0001	0.08 (0.04–0.16)	<0.0001

International, Prospective, Observational Cohort Study, n = 643 parturients
 Complete Success (33%), Partial Success (39%), EBP Failure (28.3%)

EBP Failure:

Higher if **Migraine** and ADP occurred at **L1/L3** vs. L3/L5

Higher if **EBP < 48 hrs** vs. ≥ 48 hrs

Sweden* Gupta A, et al. European Practices ADP, Failed Blood Patch. BJA 2022

CESAREAN SECTION




ASA Quality Metrics: Obstetric Anesthesia

Cesarean Delivery


- **Mode** of Anesthesia: GA vs. Regional
- Neuraxial-induced **Hypotension**
- Post-op **Opioid Consumption**

Mode of Anesthesia: Maternal Mortality with GA


Case fatality ratio 2.3:1 to 16.7:1 to 1.7:1



1979-1984




1985-1990



1991-2002

- Regional
- General

Mode of Anesthesia: **Fetal Morbidity** Worse with GA



- Neural Stem/Progenitor Cells (NPCs)
- Neuron Creation, Migration, Differentiation, Synapsis Formation, Reorganization
- **GABA** agonism
NMDA antagonism

Jevtovic-Todorovic V, J Neurosci 2003

Soriano S, Anesth 2005; BMJ 2019; A&A 2020

Palanisamy A, et al. Anesth 2011; Behav Brain 2017

Hooijamans CR, SR + Meta. Nature Scientific Reports 2023

Management of Hypotension: Venous System





Figure 1

Tsen LC, Gelman S. The Venous System during Pregnancy. Part 1: Physiologic Considerations. Part 2. Clinical Considerations. IJOA 2022;50:

Management of Hypotension: Venous System



Tsen LC, Gelman S. The Venous System during Pregnancy. Part 1: Physiologic Considerations. Part 2. Clinical Considerations. IJOA 2022;50:

Management of Hypotension: Vasopressors

Table 1 Comparison of commonly used vasopressors.

	Ephedrine	Phenylephrine	Metaraminol	Noradrenaline	Adrenaline	Mephentermine
Receptor	$\beta_1, \beta_2, \text{weak } \alpha$	α_1	$\alpha_1, \text{weak } \beta$	α_1, β	α_1, β	α_1, β
Mechanism	Indirect, weak direct	Direct	Direct and indirect	Direct	Direct	Indirect
Onset	Slow	Immediate	1–2 min	Immediate	Immediate	Immediate
Duration	Prolonged	Intermediate	Prolonged	Short	Short	Prolonged

Fetal Acidosis

Second Line:
If low HR

First Line: Goal: SBP > 90% Base
Infusion: 25-50 mcg/min
Start with Spinal

35 Studies

Management of Hypotension: Vasopressors

Table 1 Comparison of commonly used vasopressors.

	Ephedrine	Phenylephrine	Metaraminol	Noradrenaline	Adrenaline	Mephentermine
Receptor	$\beta_1, \beta_2, \text{weak } \alpha$	α_1	$\alpha_1, \text{weak } \beta$	α_1, β	α_1, β	α_1, β
Mechanism	Indirect, weak direct	Direct	Direct and indirect	Direct	Direct	Indirect
Onset	Slow	Immediate	1–2 min	Immediate	Immediate	Immediate
Duration	Prolonged	Intermediate	Prolonged	Short	Short	Prolonged

Maternal Bradycardia

Phenylephrine 0.18
(0.11-0.29)

Metaraminol 0.11 (0.04-0.26)
Norepinephrine 0.13 (0.06-0.28)


109 Studies (n = 8561)

Fitzgerald JP, et al. Prevention of Hypotension after Spinal Anaesthesia for Caesarean Section: A Systematic Review and Network Meta-Analysis of RCTs. Anaesthesia 2019

Management of Hypotension: Vasopressors

Table 1 Comparison of commonly used vasopressors.

	Ephedrine	Phenylephrine	Metaraminol	Noradrenaline	Adrenaline	Mephentermine
Receptor	$\beta_1, \beta_2, \text{weak } \alpha$	α_1	$\alpha_1, \text{weak } \beta$	α_1, β	α_1, β	α_1, β
Mechanism	Indirect, weak direct	Direct	Direct and indirect	Direct	Direct	Indirect
Onset	Slow	Immediate	1–2 min	Immediate	Immediate	Immediate
Duration	Prolonged	Intermediate	Prolonged	Short	Short	Prolonged



Heesen, M, et al. Systematic Review of Phenylephrine vs Noradrenaline for Management of Hypotension Associated with Neuraxial Anaesthesia for Caesarean Section Anaesthesia 2020;

Management of Hypotension: Vasopressors

Table 1 Comparison of commonly used vasopressors.

	Ephedrine	Phenylephrine	Metaraminol	Noradrenaline	Adrenaline	Mephentermine
Receptor	$\beta_1, \beta_2, \text{weak } \alpha$	α_1	$\alpha_1, \text{weak } \beta$	α_1, β	α_1, β	α_1, β
Mechanism	Indirect, weak direct	Direct	Direct and indirect	Direct	Direct	Indirect
Onset	Slow	Immediate	1–2 min	Immediate	Immediate	Immediate
Duration	Prolonged	Intermediate	Prolonged	Short	Short	Prolonged

Goal: SBP > 90% Base
Infusion: 2.5 mcg/min
Bolus: 5 mcg/mL
Start with Spinal

Heesen, M, et al. Systematic Review of Phenylephrine vs Noradrenaline for Management of Hypotension Associated with Neuraxial Anaesthesia for Caesarean Section Anaesthesia 2020;

Management of Hypotension: Vasopressors

Table 1 Comparison of commonly used vasopressors.

	Ephedrine	Phenylephrine	Metaraminol	Noradrenaline	Adrenaline	Mephentermine
Receptor	$\beta_1, \beta_2, \text{weak } \alpha$	α_1	$\alpha_1, \text{weak } \beta$	α_1, β	α_1, β	α_1, β
Mechanism	Indirect, weak direct	Direct	Direct and indirect	Direct	Direct	Indirect
Onset	Slow	Immediate	1–2 min	Immediate	Immediate	Immediate
Duration	Prolonged	Intermediate	Prolonged	Short	Short	Prolonged

1 mcg/kg/min

Hypotension

Fetal Acidosis

Bradycardia

0.1 mcg/kg/min

Wang YB, et al. Comparison of Continuous Infusion of Epinephrine and Phenylephrine on Hemodynamics during Spinal Anesthesia for Cesarean Delivery: A RCT. Clin Ther 2020; 42:2001-9; Biricik E, et al. Rev Bras Anesthesiol 2020;70:500-7.

Management of Uterine Tone

Oxytocin

Carbetocin

Bolus 1IU/30s Elective
 Bolus 3IU/30s Intrapartum
 Infusion: 2.5-7.5 IU/hr

Bolus 100 IU/30s

Potency

0.35 IU

Elective

14.8 mcg

0.78 IU

Elective
 BMI > 40

68 mcg

2.99 IU

Labor
 Arrest

121 mcg

Duration





Carvalho JCA, et al. AJOG 2004; Balki M, et al. Ob Gyn 2006; Khan M, et al. Can J Anaesth 2014; Nguyen-Lu N, et al. Can J Anaesth 2015; Heesen M, et al. International Consensus Statement, Anaesthesia 2019; Drew T, et al. Anaesthesia 2020; Peska E, et al. Anaesthesia 2021

Management of Uterine Tone

Oxytocin
5 IU

Carbetocin
100 mcg

Placebo



min


Rule of Three's Algorithm for Uterotonic Agents

Tsen LC, Balki M.
IJOA 2010;19:243-5

Methergine
0.2 mg IM

Hemebate
0.25 mg IM


Cytotec
600 mg B



ERAS

- **General/Process Metrics**
- **Maternal Outcomes**
- **Neonatal Outcomes**
- LOS, Pathway Compliance
- Analgesia Satisfaction
- Breastfeeding Rate
- Preoperative Fasting
- Postpartum Opioids Use/
Amount
- First Fluid, Solid Intake
- PONV
- First Mobilization
- Readmission Rate
- Urinary Catheter Removal
- Quality of Recovery

NOVEL



Novel: In Utero Fetal Surgery



Anesthesia

Uterine Relaxation

Maternal Hypotension


Pulmonary Edema

Neurocognitive Development?

Spina Bifida Repair

Open Maternal-Fetal Surgery

Minimally Invasive Fetoscopic Repair




Chmait RH, et al. Advances in Fetal Surgical Repair of Open Spina Bifida. Obstet Gynecol 2023;141:505-21.


Novel: In Utero Fetal Surgery

- 73 preclinical animal studies, > 1 MAC, single long (> 3hrs) or multiple exposures

Impaired Learning & Memory




Increased Apoptosis



Bleeser T, et al. Effects of General Anaesthesia on Neurocognitive Development of the Fetus: A Systematic Review and Meta-Analysis. BJA 2021; Bleeser T, et al. Neurodevelopmental Outcomes After Prenatal Exposure to Anaesthesia Anaesthesia 2023;78:159-69.


Novel: OMICS

- Gene (Transcriptomics)
- Proteins (Proteomics)
- Metabolites (Metabolomics)
- Microbiota (Microbiomics)
- Epigenome (Epigenomics)



Rahnavard A, et al.
Research Square. 11/16/22

Novel OMICS



Outcome	Sample GA (weeks)	AUC	Sensitivity	Specificity	Predictor Symbols (% inclusion in best combination)
Early PE	8–16	0.55	0.21	0.90	gpIIbIIIa(34%)
Early PE	16.1–22	0.65	0.31	0.90	Soggy-1(26%); IMDH2(20%); Siglec-6(14%); PKC-D(12%); MMP-12(10%); RBP(10%)
Early PE	22.1–28	0.89	0.77	0.90	Siglec-6(72%); Activin A(63%); VEGF121(34%)
Early PE	28.1–32	0.93	0.82	0.90	Siglec-6(72%); ALCAM(15%); FCN2(14%); VEGF121(12%)

ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the receiver operating characteristic curve; early PE: early preeclampsia; *FCN2*: ficolin 2; GA: gestational age; gpIIbIIIa: glycoprotein IIb/IIIa; IMDH2: inosine-5'-monophosphate dehydrogenase (IMDH2); MMP: matrix metalloproteinase; PKC-D: protein kinase C delta type; RBP: retinol binding protein; Siglec-6: sialic acid binding immunoglobulin-like lectin; VEGF121: vascular endothelial growth factor A, isoform 121. Only proteins selected in 10% or more of the 200 bootstrap iterations are listed.

Rahnavard A, et al. Research Square. 11/16/22; Tarca AL et al. Prediction of Early Preeclampsia. Longitudinal Proteomics. PLoS One, 2019; Ghaemi MS, et al. J Matern Fetal Med 2021

What's New in Obstetric Anesthesia

MORBIDITIES

REGIONAL

SECTION

NON-OB

Questions?





OFFICIAL SELECTION
HAMPTONS
FILM FESTIVAL

COIN OPERATED

A Short Film
by
Nicholas Arioli



OFFICIAL SELECTION
LA SHORTS
FILM FESTIVAL
2017

OFFICIAL SELECTION
ST LOUIS
FILM FESTIVAL
2017

OFFICIAL SELECTION
GUANAJUATO
FILM FESTIVAL
2017

OFFICIAL SELECTION
SAN JOSE INTL
SHORT FILM FEST
2017

OFFICIAL SELECTION
CINEKID
FILM FESTIVAL
2017

OFFICIAL SELECTION
CHICAGO INTL
CHILDRENS FESTIVAL
2017

OFFICIAL SELECTION
SANTA FE IND
FILM FESTIVAL
2017

OFFICIAL SELECTION
CORONADO
ISLAND FILM FEST
2017

OFFICIAL SELECTION
ST CLOUD
FILM FESTIVAL
2017

OFFICIAL SELECTION
FUNCINEMA
FILM FESTIVAL
2017

OFFICIAL SELECTION
SPARK
ANIMATION FESTIVAL
2017